肿瘤基因组学研究组 研究组长 陈国强
陈国强 研究员 研究组长
gqchen@sibs.ac.cn
chengq@shsmu.edu.cn
学习经历
1980-1985 湖南南华大学（原衡阳医学院）医疗系，1985年获学士学位
1985-1988 上海第二医科大学病理生理学硕士
1993-1996 上海第二医科大学血液学博士
1997 法国巴黎Saint-Louis医院访问学者
1999-2001 美国Mount-Saint医学院访问学者
工作简历
1985-1993 衡阳医学院心血管病研究所，病理生理教研室
1988-1993 湖南衡阳医学院病理生理教研室，1991年12月获讲师任职资格
1996-1999 上海第二医科大学附属瑞金医院血液学研究所，1996年11月破格晋升副研究员。
1998-1999 兼任上海第二医科大学生物学教研室副主任
1999-至今 《癌症》杂志副主编，常务编委
1999-至今 上海交通大学医学院附属瑞金医院，上海血液学研究所研究员
1999-2001 美国Mount-Saint医学院visiting assistant professor
2000-至今 上海市青年联合会委员
2002-至今 中国科学院上海生命科学院健康科学中心研究室主任
上海交通大学医学院病理生理学教研室主任
细胞分化与凋亡教育部重点实验室主任
2006 《生理学报》副主编，中国病理生理学学会常务理事，上海生理学会副理事长
2006-至今 上海交通大学医学院副院长，研究生院院长
荣誊(证书、称号、会员)
2005 上海科技进步奖 一等奖（第一完成人） 上海市人民政府
2005 上海医学科技奖 一等奖（第一完成人） 中华医学会
2005 中华医学科技奖 一等奖（第一完成人） 中华医学会上海分会
2005 上海医学科技奖 一等奖（第一完成人） 中华医学会上海分会
2004 上海医学科技奖 一等奖（第二完成人） 中华医学会上海分会
2003 教育部提名国家自然科技奖 二等奖（第四完成人） 教育部
2000 国家自然科学奖 二等奖（第四完成人） 国务院
2000 杜邦科技创新奖 第四完成人 国家科技部
1997 上海市科技进步奖 一等奖（第三完成人） 上海市人民政府
2005 上海医学领军人才， 上海市人事局、组织部
2005 全国先进工作者 国务院
2005 上海市自然科学牡丹奖 上海市人民政府
2004 上海市劳动模范 上海市人民政府
2004 中国青年科技奖 中国科协
2004 上海市自然科学牡丹奖 上海市科技奖励委员会
2004 新世纪百千万人才工程首批国家级人选 国家人事部、中组部等
2004 上海第二医科大学首届校长“管理”奖 上海第二医科大学
2003 上海市优秀学科带头人 上海市科委
2003 上海优秀留学回国人员 上海市人民政府
2003 上海市留学回归人员一类资助人员 上海市人事局
2002 上海市“十大杰出青年” 上海市团委等
2001 中国科学院“百人”计划入选者 中国科学院
2000 国务院特殊津贴 国务院
1999 上海市优秀青年教师 上海市教委
1999 上海市卫生系统杰出青年人才“银蛇奖” 上海市卫生局
1999 上海市卫生局行政记大功一次 上海市卫生局
1997 上海市科协科技论文二等奖 上海市科协
1997 国家杰出青年基金获得者 国家自然科学基金委员会
1997 上海市优秀青年教师 上海市教委
主要成果
该研究组一直致力于白血病细胞分化和凋亡的分子机制和治疗学基础研究，取得系列重要发现。
例如，所从事的三氧化二砷治疗急性早幼粒细胞性白血病（APL）的基础和临床研究工作引起国
际同行的高度重视; 在发现低氧诱导白血病细胞分化的基础上，提出以“低氧-低氧诱导因子（HIF-1a）
-C/EBPa”为主轴的白血病细胞分化理论；报道磷脂爬行酶介导白血病分化，并就其表达调控机制提
出新发现；发现包括新型喜树碱衍生物NSC606985在内的系列化合物诱导白血病细胞凋亡，并对其
诱导细胞凋亡的机制进行了研究，展示良好的药物研发前景。此外，在利用蛋白质组学技术研究和白
血病相关蛋白的功能方面也取得重要进展。这些发现不仅对于深入认识造血细胞分化和凋亡分子信息
学基础和白血病发病的分子机制机制具有重要科学价值，也为诱导分化和凋亡治疗模式在其它类型白
血病的突破奠定了重要的实验基础。
主要论文
Xiao S, Li D, Zhu HQ, Song MG, Pan XR, Jia PM, Peng LL, Dou AX, Chen GQ, Chen SJ, Chen Z, Tong JH. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16448-53.
Pan XY, Chen GQ, Cai L, Buscemi S, Fu GH. Anion exchanger 2 mediates the action of arsenic trioxide. Br J Haematol. 2006 Sep;134(5):491-9.
Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, Aradi J, Lanotte M, Tong JH, Chen GQ, Segal-Bendirdjian E. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci. 2006 Jul 1;119(Pt 13):2797-806.
Lu Y, Xu YB, Yuang TT, Song MG, Michael Lubbert, Manfred Fliegauf, Chen GQ. Inducible Expression of AML1-ETO Fusion Protein Endows Leukemic Cells with Susceptibility to Extrinsic and Intrinsic apoptosis. Leukemia, 2006;20(6):987-93. (IF=6.612)
Huang Y, Zhao Q, Zhou CX, Gu ZM, Li D, Xu HZ, Perter J. Sims, Zhao KW, Chen GQ. Anti-leukemic Roles of Human Phospholipid Scramblase 1 Gene, Evidence from Inducible PLSCR1-expressing Leukemic Cells, Oncogene 2006 Oct 26;25(50):6618-27. (IF=6.872)
Ren H, Cao Y, Zhao Q, Li J, Zhou C, Liao L, Jia M, Zhao Q, Cai H, Han ZC, Yang R, Chen G, Zhao RC. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun. 2006 Aug 18;347(1):12-21.
Han YH, Xia L, Song LP, Zheng Y, Chen WL, Zhang L, Huang Y, Chen GQ, Wang LS. Comparative Proteomic Analysis of Hypoxia-treated and Untreated Human Leukemic U937 cells. Proteomics, 2006;(6):3262-3274. (IF=6.088)
Li X, Xu YB, Wang Q, Lu Y, Wang YC, Lubbert Michael, Zhao KW, Chen GQ. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML1-ETO-induced growth arrest in leukemic cells. J Cellular Physiology, 2006;208:594-601. (IF=4.362)
Jin X, Xia L, Wang LS, Shi JZ, Zheng Y, Chen WL, Zhang L, Liu ZG, Chen GQ and Fang NY. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics, 2006, 6:1948-1956. (IF=6.088)
Lei Zhang, Wang LS, Xia L, Chen WL, Zheng Y and Chen GQ. Comparative proteomic analysis of human leukemic cells with and without inducible expression of leukemogenic AML1-ETO protein. Chinese J Physiology 2006 Aug 31;49(4):182-91. (IF=0.463)
Guo M, Jiang Y, Liu W, Song LP, Yu Y, and Chen GQ. Hypoxia-mimetic Agents Desferrioxamine and cobalt chloride induce leukemic cell apoptosis respectively through nitric oxide-dependent and independent mechanisms. Apoptosis, 2006; 11:67-77. (IF=4.497)
Liu W, Guo M, Xu YB, Dao L, Zhou ZN, Wu YL, Chen Z, Kogan SC, Chen GQ. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood. 2006; 107(2) 2006;698-707. (IF=10.131)
Zhao KW, Li D, Zhao Q, Huang Y, Silverman RH, Sims PJ, Chen GQ. Interferon-alpha induced expression of phospholipid scramblase 1 through STAT1 required the sequential activation of protein kinase Cdelta & JNK. J Biol Chem. 2005;280(52):42707-42714. (IF=5.854)
Yan H, Peng ZG, Wu YL, Jiang Y, Yu Y, Huang Y, Zhu YS, Zhao Q, Chen GQ. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica. 2005;90(12):1607-1616. (IF=4.575)
Li Z, Liu Q, Song M, Zheng Y, Nan P, Cao Y, Chen GQ, Li Y, Zhong Y. Detecting correlation between sequence and expression divergences in a comparative analysis of human serpin genes. Biosystems. 2005;82(3):226-34. (IF=1.144)
Fu GH, Wang Y, Xi YH, Guo ZW, Liu XB, Bai SZ, Yang BF, Chen GQ. As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein(dagger). J Drug Target. 2005 ;13(4):235-43. (IF=1.569)
Xue ZH, Jiang Y, Yu Y, Wang LS, Chen GQ, Zhao Q. Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor-1alpha protein. Biochem Biophys Res Commun. 2005;332(4):1140-5. (IF=3)
Jiang Y, Xue ZH, Shen WZ, Du KM, Yan H, Yu Y, Peng ZG, Song MG, Tong JH, Chen Z, Huang Y, Lubbert M, Chen GQ. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia. 2005 ;19(7):1239-47. (IF=6.612)
Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, Zhang WH, Peng CH, Zhang SD,Li HW, Chen GQ. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology. 2005;68(1):79-86. (IF=2.38)
Fu GH, Wang Y, Xi YH, Shen WW, Pan XY, Shen WZ, Jiang XS, Chen GQ. Direct interaction and cooperative role of tumor suppressor p16 with band 3 (AE1).FEBS Lett. 2005;579(10):2105-10. (IF=3.415)
Song MG, Gao SM, Du KM, Xu M, Yu Y, Zhou YH, Wang Q, Chen Z, Zhu YS, Chen GQ. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms.Blood. 2005;105(9):3714-21. (IF=10.131)
Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, Jin XL, You JH, Yang G, Shen ZX, Chen J, Xiong SM, Chen GQ, Xu F, Liu YW, Chen Z, Chen SJ. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A. 2005;102(4):1104-9. (IF=10.231)
Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, Zhang J, Chen GQ, Chen SJ, Chen Z. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104(13):4219-25. (IF=10.131)
Zhao KW, Li X, Zhao Q, Huang Y, Li D, Peng ZG, Shen WZ, Zhao J, Zhou Q,Chen Z, Sims PJ, Wiedmer T, Chen GQ. Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood. 2004;104(12):3731-8. (IF=10.131)
Zhao Q, Tao J, Zhu Q, Jia PM, Dou AX, Li X, Cheng F, Waxman S, Chen GQ, Chen SJ, Lanotte M, Chen Z, Tong JH. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation. Leukemia. 2004;18(2):285-92. (IF=6.612)
Huang Y, Du KM, Xue ZH, Yan H, Li D, Liu W, Chen Z, Zhao Q, Tong JH, Zhu YS, Chen GQ. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia. 2003;17(11):2065-73. (IF=6.612)
Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, Chen GQ. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia. 2003;17(7):1333-7. (IF=6.612)
Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 2003;63(8):1853-9. (IF=7.616)
Gu BW, Xiong H, Zhou Y, Chen B, Wang L, Dong S, Yu ZY, Lu LF, Zhong M, Yin HF, Zhu GF, Huang W, Ren SX, Gallagher RE, Waxman S, Chen GQ, Wang ZG, Chen Z, Fu G, Chen SJ. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proc Natl Acad Sci U S A. 2002;99(11):7640-5. (IF=10.231)
Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 2001 Jan 1;97(1):264-9.
Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000;14(2):262-70. (IF=6.612)
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L,Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide:remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315-24. (IF=10.131)
Zhu J, Guo WM, Yao YY, Zhao WL, Pan L, Cai X, Ju B, Sun GL, Wang HL, Chen SJ, Chen GQ, Caen J, Chen Z, Wang ZY. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia.1999;13(7):1062-70. (IF=6.612)
Waxman S, Jing Yk, Chen Z, Chen GQ. RESPONSE: re: apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations J Natl Cancer Inst. 1999 Oct 6;91(19):1691.
Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 1999 ;91(9):772-8. (IF=15.171)
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL,Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89(9):3354-60. (IF=10.131)
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K,Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997 ;89(9):3345-53. (IF=10.131)
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARalpha/PML proteins. Blood. 1996; 88(3):1052-61. (IF=10.131)
专著与综述
1. Huang Y, Zhao Q, Chen GQ. Phospholipid scramblase 1.Sino Acta Physiology.
2006 Dec 25;58(6):501-510.
2. Chen GQ, Peng ZG, Liu W, Song LP, Jiang Y, Huang Y, Zhao Q. Hypoxia inducible factor-1alpha
and leukemic cell differentiation. Sino Acta Physiology 2006 Feb 25;58(1):5-13.
3. Fang J, Chen SJ, Tong JH, Wang ZG, Chen GQ, Chen Z. Treatment of acute promyelocytic leukemia with
ATRA and As2O3: a model of molecular target-based cancer therapy. Cancer Biol Ther.
2002 Nov-Dec;1(6):614-20.
4. Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ. Expanding the use of arsenic trioxide:
leukemias and beyond. Semin Hematol. 2002 Apr;39(2 Suppl 1):22-6.
5. Zhao WL, Chen SJ, Shen Y, Xu L, Cai X, Chen GQ, Shen ZX, Chen Z, Wang ZY. Treatment of acute
promyelocytic leukemia with arsenic trioxide: clinical and basic studies. Leuk Lymphoma.
2001 Nov-Dec;42(6):1265-73.
6. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL.
Oncogene. 2001 Oct 29;20(49):7146-53.
7. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute promyelocytic leukemia with arsenic
compounds: in vitro and in vivo studies. Semin Hematol. 2001 Jan;38(1):26-36.
